Response criteria for disease assessment have important therapeutic and prognostic implications in clinical trials and in routine clinical practice. The Lugano classification has been used widely for evaluation of the response of patients with lymphoma to treatment, although the alternative Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) classification was recently proposed; these criteria are compared herein.

中文翻译：

---

血液癌症：对淋巴瘤患者进行分期和再分期—更好的方法？

疾病评估的反应标准在临床试验和常规临床实践中具有重要的治疗和预后意义。Lugano分类法已被广泛用于评估淋巴瘤患者对治疗的反应，尽管最近提出了另一种替代方法《 2017年淋巴瘤反应评估标准》（RECIL 2017）。这些标准在这里进行了比较。